Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma

Adriana L. da Silva, Gisele P. de Oliveira, Namho Kim, Fernanda F. Cruz, Jamil Z. Kitoko, Natalia G. Blanco, Sabrina V. Martini, Justin Hanes, Patricia R.M. Rocco, Jung Soo Suk, Marcelo M. Morales

Research output: Contribution to journalArticlepeer-review

Abstract

Despite long-standing efforts to enhance care for chronic asthma, symptomatic treatments remain the only option to manage this highly prevalent and debilitating disease. We demonstrate that key pathology of allergic asthma can be almost completely resolved in a therapeutic manner by inhaled gene therapy. After the disease was fully and stably established, we treated mice intratracheally with a single dose of thymulin-expressing plasmids delivered via nanoparticles engineered to have a unique ability to penetrate the airway mucus barrier. Twenty days after the treatment, we found that all key pathologic features found in the asthmatic lung, including chronic inflammation, pulmonary fibrosis, and mechanical dysregulation, were normalized. We conducted tissue- and cell-based analyses to confirm that the therapeutic intervention was mediated comprehensively by anti-inflammatory and antifibrotic effects of the therapy. We believe that our findings open a new avenue for clinical development of therapeutically effective gene therapy for chronic asthma.

Original languageEnglish (US)
Article numbereaay7973
JournalScience Advances
Volume6
Issue number24
DOIs
StatePublished - Jun 2020

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma'. Together they form a unique fingerprint.

Cite this